A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, which is given via an intravenous drip every two weeks, has been proven in clinical trials to decrease amyloid plaques. It has also already been given the green light for use in the UK.

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.